CR20110032A - Derivados de tiofeno y tiazol y su uso como inhibidores de p13k - Google Patents

Derivados de tiofeno y tiazol y su uso como inhibidores de p13k

Info

Publication number
CR20110032A
CR20110032A CR20110032A CR20110032A CR20110032A CR 20110032 A CR20110032 A CR 20110032A CR 20110032 A CR20110032 A CR 20110032A CR 20110032 A CR20110032 A CR 20110032A CR 20110032 A CR20110032 A CR 20110032A
Authority
CR
Costa Rica
Prior art keywords
inhibitors
tiazol
thiophen
derivatives
inflammatory
Prior art date
Application number
CR20110032A
Other languages
English (en)
Spanish (es)
Inventor
David P Cardin
Jeffrey L Gaulin
Paul D Greenspan
Stepan Vyskocil
Tianlin; Xu
Christelle C Renou
Original Assignee
Millenium Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41010579&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR20110032(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Millenium Pharmaceuticals Inc filed Critical Millenium Pharmaceuticals Inc
Publication of CR20110032A publication Critical patent/CR20110032A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CR20110032A 2008-06-19 2011-01-17 Derivados de tiofeno y tiazol y su uso como inhibidores de p13k CR20110032A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13248408P 2008-06-19 2008-06-19

Publications (1)

Publication Number Publication Date
CR20110032A true CR20110032A (es) 2011-03-14

Family

ID=41010579

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20110032A CR20110032A (es) 2008-06-19 2011-01-17 Derivados de tiofeno y tiazol y su uso como inhibidores de p13k

Country Status (21)

Country Link
US (3) US8183240B2 (https=)
EP (1) EP2313399B1 (https=)
JP (1) JP5596026B2 (https=)
KR (1) KR20110018451A (https=)
CN (1) CN102066365A (https=)
AU (1) AU2009260782B2 (https=)
BR (1) BRPI0914223A2 (https=)
CA (1) CA2727069A1 (https=)
CL (1) CL2010001474A1 (https=)
CO (1) CO6331431A2 (https=)
CR (1) CR20110032A (https=)
EA (1) EA201170052A1 (https=)
ES (1) ES2491522T3 (https=)
GE (1) GEP20125650B (https=)
IL (1) IL210055A0 (https=)
MA (1) MA32468B1 (https=)
MX (1) MX2010014125A (https=)
NZ (1) NZ589844A (https=)
UA (1) UA106206C2 (https=)
WO (1) WO2009154741A1 (https=)
ZA (1) ZA201008875B (https=)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5581219B2 (ja) 2008-01-25 2014-08-27 ミレニアム ファーマシューティカルズ， インコーポレイテッド チオフェンおよびホスファチジルイノシトール３−キナーゼ（ｐｉ３ｋ）阻害薬としてのその使用
JP5596026B2 (ja) * 2008-06-19 2014-09-24 ミレニアム ファーマシューティカルズ， インコーポレイテッド チオフェン又はチアゾール誘導体及びｐｉ３ｋ阻害剤としてのそれらの使用
WO2010090716A1 (en) * 2009-01-30 2010-08-12 Millennium Pharmaceuticals, Inc. Heteroaryls and their use as pi3k inhibitors
US9090601B2 (en) * 2009-01-30 2015-07-28 Millennium Pharmaceuticals, Inc. Thiazole derivatives
US8796314B2 (en) 2009-01-30 2014-08-05 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
MX2013001660A (es) * 2010-08-11 2013-06-03 Millenium Pharmaceuticals Inc Heteroarilos y usos de los mismos.
WO2012021611A1 (en) * 2010-08-11 2012-02-16 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
US8859768B2 (en) 2010-08-11 2014-10-14 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
JP5726635B2 (ja) 2010-08-25 2015-06-03 株式会社Ｎｔｔドコモ マルチモードフロントエンド回路
TW201307309A (zh) 2010-10-13 2013-02-16 Millennium Pharm Inc 雜芳基化合物及其用途
CN102503930B (zh) * 2011-10-28 2014-07-02 浙江大学 3,4,5,-三取代氨基噻吩类化合物及其制备和用途
DK2790705T3 (en) 2011-12-15 2018-03-12 Novartis Ag Use of inhibitors of the activity or function of PI3K
WO2013096630A1 (en) * 2011-12-23 2013-06-27 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
EP2825889A4 (en) * 2012-03-14 2015-10-28 Salk Inst For Biological Studi ADENOVIRAL TUMOR DIAGNOSIS
AU2014236207B2 (en) 2013-03-14 2019-05-23 Salk Institute For Biological Studies Oncolytic adenovirus compositions
WO2014144850A1 (en) 2013-03-15 2014-09-18 Genentech, Inc. Methods of treating cancer and preventing cancer drug resistance
BR112016018691A2 (pt) * 2014-02-14 2017-08-08 Univ British Columbia Compostos do domínio de ligação ao dna (dbd) de receptor de andrógeno humano como terapêuticos e métodos para seu uso
KR20250081944A (ko) 2014-09-24 2025-06-05 솔크 인스티튜트 포 바이올로지칼 스터디즈 종양 살상 바이러스 및 이의 사용방법
EP4155411A1 (en) 2016-02-23 2023-03-29 Salk Institute for Biological Studies Exogenous gene expression in therapeutic adenovirus for minimal impact on viral kinetics
WO2017147265A1 (en) 2016-02-23 2017-08-31 Salk Institute For Biological Studies High throughput assay for measuring adenovirus replication kinetics
EP3532082A4 (en) 2016-12-12 2020-08-26 Salk Institute for Biological Studies SYNTHETIC ADENOVIRUS TUMOR TARGETING AND THEIR USES
MX2020010499A (es) 2018-04-09 2020-10-28 Salk Inst For Biological Studi Composiciones de adenovirus oncoliticas con propiedades aumentadas de replicacion.
WO2020261144A1 (en) * 2019-06-28 2020-12-30 Pfizer Inc. 5-(thiophen-2-yl)-1h-tetrazole derivatives as bckdk inhibitors useful for treating various diseases
CN110759900B (zh) * 2019-10-25 2021-07-30 沈阳药科大学 噻吩类化合物的制备方法和用途
US20230046892A1 (en) 2019-12-20 2023-02-16 Bayer Aktiengesellschaft Substituted thiophene carboxamides, thiophene carboxylic acids and derivatives thereof
CN113527281B (zh) * 2020-04-20 2023-12-22 昆山彭济凯丰生物科技有限公司 杂环化合物及其制备方法和应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DD275870A1 (de) 1988-09-27 1990-02-07 Univ Leipzig Verfahren zur herstellung von in 5-position verschiedenartig substituierten 3-aminothiophen-4-carbonitrilen
WO2006078287A2 (en) 2004-05-06 2006-07-27 Plexxikon, Inc. Pde4b inhibitors and uses therefor
GB0508472D0 (en) * 2005-04-26 2005-06-01 Glaxo Group Ltd Compounds
MX2008013578A (es) 2006-04-26 2009-03-23 Hoffmann La Roche Derivados de tieno [3,2-d]pirimidina utiles como inhibidores de fosfatidilinositol 3-cinasa(p13k).
EP2016075A1 (en) * 2006-05-03 2009-01-21 AstraZeneca AB Thiazole derivatives and their use as anti-tumour agents
MX2009002046A (es) 2006-08-24 2009-03-06 Astrazeneca Ab Derivados de morfolino pirimidina utiles en el tratamiento de trastornos proliferativos.
WO2009042607A1 (en) * 2007-09-24 2009-04-02 Genentech, Inc. Thiazolopyrimidine p13k inhibitor compounds and methods of use
JP5581219B2 (ja) * 2008-01-25 2014-08-27 ミレニアム ファーマシューティカルズ， インコーポレイテッド チオフェンおよびホスファチジルイノシトール３−キナーゼ（ｐｉ３ｋ）阻害薬としてのその使用
JP5596026B2 (ja) * 2008-06-19 2014-09-24 ミレニアム ファーマシューティカルズ， インコーポレイテッド チオフェン又はチアゾール誘導体及びｐｉ３ｋ阻害剤としてのそれらの使用

Also Published As

Publication number Publication date
US8183240B2 (en) 2012-05-22
CO6331431A2 (es) 2011-10-20
IL210055A0 (en) 2011-02-28
CN102066365A (zh) 2011-05-18
WO2009154741A1 (en) 2009-12-23
US20100075951A1 (en) 2010-03-25
AU2009260782A1 (en) 2009-12-23
MA32468B1 (fr) 2011-07-03
US20130217689A1 (en) 2013-08-22
EP2313399A1 (en) 2011-04-27
WO2009154741A8 (en) 2010-03-25
ES2491522T3 (es) 2014-09-08
JP2011524904A (ja) 2011-09-08
CA2727069A1 (en) 2009-12-23
BRPI0914223A2 (pt) 2019-09-24
ZA201008875B (en) 2012-02-29
UA106206C2 (ru) 2014-08-11
CL2010001474A1 (es) 2011-04-29
JP5596026B2 (ja) 2014-09-24
MX2010014125A (es) 2011-02-24
US8440664B2 (en) 2013-05-14
AU2009260782B2 (en) 2014-12-11
KR20110018451A (ko) 2011-02-23
EA201170052A1 (ru) 2011-06-30
US20120202812A1 (en) 2012-08-09
NZ589844A (en) 2012-11-30
GEP20125650B (en) 2012-09-25
EP2313399B1 (en) 2014-05-28

Similar Documents

Publication Publication Date Title
CR20110032A (es) Derivados de tiofeno y tiazol y su uso como inhibidores de p13k
UY33554A (es) Heteroarilos y usos de los mismos
CO6321282A2 (es) Derivados de piperidinilindol como inhibidores de aldosterona sintasa
DOP2013000036A (es) Derivados de ciclobutano como inhibidores de jak
CL2011002739A1 (es) Compuestos derivados de 3-(1h-pirrolo[2,3-b]piridina-3-carbonil)-bencenosulfonamida; composicion farmaceutica que los comprende; kit; y su uso como inhibidores de raf para el tratamiento de una enfermedad o condicion seleccionada de melanoma, glioma, glioblastoma multiforme, cancer colorrectal, cancer de pulmon, entre otras.
UY32303A (es) Tiolactamas y sus usos
UY34051A (es) Derivados de pirrolotriazinona como inhibidores de pi3k
DOP2011000217A (es) Nuevas bencenosulfonamidas como bloqueadores de canales de calcio
UY32049A (es) Inhibidores de cmet
CL2011001333A1 (es) Compuestos derivados de heterociclos nitrogenados sustituidos, inhibidores de ns5a; composicion farmaceutica; y su uso para el tratamiento de la hepatitis c.
ECSP11010798A (es) 1,2,5-oxadiazoles como inhibidores de indolamina 2,3-dioxigenasa
DOP2014000033A (es) Aminoquinazolinas como inhibidores de quinasa
EA201170252A1 (ru) Амидофеноксиндазолы в качестве ингибиторов c-мет
UY33503A (es) Imidazo [1,2-a]pirimidinas y piridinas sustituidas
BR112012008385A2 (pt) inibidores de p13 cinase e uso dos mesmos.
CL2011000846A1 (es) Compuestos heterociclicos sustituidos; composicion farmaceutica; y su uso para el tratamiento de la hepatitis c.
UY32529A (es) Compuestos heterocíclicos y su uso como inhibidores de la glucógeno sintetasa quinasa 3
DOP2013000082A (es) Heteroarilos y sus usos
EA201491376A1 (ru) Производные 1h-пирроло[2,3-b]пиридина и их применение в качестве ингибиторов киназы
EP2603216A4 (en) HETEROARYLE AND USES THEREOF
CU24052B1 (es) Derivados de anilina-pirimidina sustituidos con sulfoximina como inhibidores de quinasas dependientes de ciclina (cdk), y método de producción de los mismos
ECSP099675A (es) Compuestos heterocíclicos, composición y métodos de uso
CR20160070A (es) Compuestos de triazolopiridina, composiciones y métodos de uso de los mismos
BR112015005562A2 (pt) compostos de aminoisoquinolina, suas composições e uso dos novos compostos como inibidores da proteína quinase.
UY35332A (es) Derivados de pirrolotriazina como inhibidores de pi3k

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)